Pharvaris (PHVS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.41B and a free-cash-flow yield of -6.8%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 2.7/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Rising · +45.3% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-20.5%
How far the last close sits under the highest price of the past five years.
Market cap
$2.41B
Trailing P/E
—
Price / book
7.2
Price / sales
—
FCF yield
-6.8%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
-2.5
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
PHVS earnings
Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$0.72).
Beat the EPS estimate in 1 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 12, 2026
-$0.70
-$0.65
-7.7%
$0
Q1 2026
Apr 2, 2026
-$0.71
-$0.62
-14.5%
$0
Q3 2025
Nov 12, 2025
-$0.60
-$0.67
+10.4%
$0
Q2 2025
Aug 12, 2025
-$0.83
-$0.77
-7.8%
$0
PHVS analyst price target
Median target $59.52 from 14 analysts, ranging $40.81 – $78.62.
Nama's AI scorecard currently rates Pharvaris Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does PHVS report earnings?
Pharvaris's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.72.
What is the PHVS price target?
The median analyst price target from 14 analysts is $59.52, with a range of $40.81 – $78.62.
Is PHVS Shariah compliant?
Nama's AAOIFI-style screen reads Pharvaris as Can't Tell. A figure the screen needs is missing, so it can't tell.